Phakic Intraocular Lenses (IOL) Market is projected to reach US$ 819.5 Million by the end of 2032

[280 Pages Report] As per Future Market Insights’ latest analysis, the global phakic intraocular lenses (IOL) market reached US$ 344.4 Mn in 2021. Sales are projected to grow at a 9.5% CAGR over the forecast period, with the market valuation reaching US$ 819.5 Mn in 2032.

Patients with high ametropia or contraindications to laser refractive surgery are treated with phakic intraocular lenses (pIOLs). The key aspect that makes these lenses ideal for use in young adults seeking ocular prescription independence is the preservation of accommodation, as lens extraction is not required.

Furthermore, as the number of people who are myopic has increased in recent years, this refractive correction option has become increasingly significant. Simultaneously, it is an important area of research in light of future estimates of the prevalence of simple myopia and, more importantly, severe myopia.

Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15128

Because of the aesthetic and optical constraints of the conventional ophthalmic lens, as well as growing trend of contact lens overuse, phakic IOLs are a viable option for individuals with severe myopia.

Although phakic intraocular lenses have some benefits over laser refractive surgery, such as reversibility, enhanced optical quality in high ametropias, and a wider range of correction, etc., it is important to remember that it is a surgical procedure with all of the risks that are associated with intraocular surgeries, including severe complications including endophthalmitis.

Growing concerns with increasing ocular disease indication burden, high prevalence of diabetes and associated retinopathy, as well as the development of alternatives to removable spectacles and lenses for corrective vision are chief factors expected to drive the market.

“Advances in excimer laser procedures have presented a gateway into the development of implantable intraocular lenses with effective vision correction outcomes. Such developments are anticipated to auger well for the market over the forecast period,” says an FMI analyst.  

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-15128

Key Takeaways:

  • Based on product type, the posterior chamber phakic IOL segment accounted for 0% of the total market share in 2021 and the trend is expected to continue through 2032.
  • By indication, sales in the astigmatism segment will increase at a 8.5% CAGR over the assessment period.
  • In terms of end user, the hospitals segment will remain most lucrative over the forecast period.
  • The U.S. is expected to lead the North America phakic intraocular lenses market over the assessment period.
  • Demand in China is expected to grow at a 10.5% CAGR through 2032.
  • Germany will emerge as a lucrative pocket, with sales rising at a 9.3% CAGR over the forecast period.

Competition Landscape

Key players are investing in research and development to offer patient-specific and indication-specific pIOLs to enhance procedural outcomes. They are also focusing on new product launch activities, licensing of product sales within a specific region, as well as regulations associated with new device development and manufacturing. For instance:

  • In January 2019, owing to the high regulatory standards, precision and quality requirements in Germany and Japan, Star Surgical announced expanded recommended diopter range for their EVO Visian ICL in both the countries.
  • In December 2019, Johnson & Johnson Vision announced the Food and Drug Administration (FDA) approval and U.S. launch of TECNIS Toric II 1-Piece Intraocular Lens (IOL).

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/15128

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the phakic intraocular lenses (IOL) market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research study is based on the product – (posterior chamber phakic IOL, and anterior chamber phakic IOL), by indication (myopia, hyperopia, and astigmatism), by end user (hospitals, ophthalmology clinics, and ambulatory surgical centres), across seven key regions of the world.

About Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

INR Test Meter Market is estimated to enjoy a valuation of US$ 1.3 Bn by the end of 2022

[300+ Pages Report] The market for INR test metres is anticipated to reach US$ 1.3 billion by the end of 2022, growing at a CAGR of 6.3 percent, and surpassing US$ 2.4 billion by 2032. With a market share of approximately 79.7% in 2021, the devices segment dominated the global INR test metre market in terms of product type.

As per Future Market Insights, the global INR test meter market was around US$ 1.2 Bn in 2021, and is projected to exhibit a CAGR growth of close to 6.3% over the forecast period, exceeding valuation of US$ 2.4 Bn in 2032.

Patients with coagulopathic aberrations related to pathological conditions have a strong reliance on PT diagnostic platforms. Patients who take warfarin frequently have medical conditions that put them at high risk for severe illness, including hospitalization, intensive care admissions, and death, as per the Centers for Disease Control and Prevention.

Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15124

With the emerging importance of utilizing point-of-care tests, the market for INT test meters is set to witness high demand during the forecast period (2022-2032). One of the primary factors driving the growth of the INR test mater market is rising prevalence of cardiovascular diseases and blood disorders across the globe.

Demand for INR test meters is expected to grow due to increased awareness of these disorders, which will improve diagnostic rates and preventive care management. Further, with favorable government funds and investments for acquiring and installing such medical devices in public healthcare facilities, the demand in the market is projected to surge through 2022 & beyond.

Key Takeaways from Market Study

  • In terms of product, devices held approximately 7% of market value share in 2021, owing to their efficacy in delivering positive therapeutic outcomes.
  • Based on end users, hospitals segment is expected to register a CAGR of 8% during the forecast period.
  • North America is considered as the leading region with a value share of 6% in 2021, owing to high lifestyle associated disease cases, and rapid device approvals.
  • The U.K. is expected to lead the growth in Europe INR test meter market backed by its development in healthcare infrastructure

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-15124

“Growing advancements of digital solutions for medical use is set to propel the sales of the INR test meter market across the globe,” says an analyst of Future Market Insights.

Market Competition

Key manufacturers in the INR test meter market are adopting strategic approaches such as mergers and research activities for revenue growth and product portfolio expansion. Producers are also engaged in several patent expiry mitigation approaches to further provide upgraded product lines, thus establishing a strong geographical outlook.

  • In November 2021, CoaguSense Inc. incorporated a novel “Prothrombin Time Home Testing System” connected with MedM remote care platform.
  • In May 2021, Biosynex acquired Avalun to become a European leader in rapid diagnostic testing.

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/15124

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the INR test meter market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032.

The research study is based on the product – (device, lancet, and test strips), by end user (hospitals, speciality clinics, ambulatory surgical centres, and home care settings), across seven key regions of the world.

About Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Systemic Lupus Erythematous SLE Drugs Market to reach a valuation of US$ 329.18 Billion by 2032

[250 Pages Report] Global systemic lupus erythematous drugs market growth is fast in North American region and is estimated to project remarkable CAGR growth throughout forecast period. In North America, the SLE is more prevalent among Hispanics, Asians, and Native Americans according to Centers for Disease Control and Prevention (CDC). The second largest and fastest growing global systemic lupus erythematous drugs market is Europe and is projected to reach nearly US$ 550 Mn and register a double digit CAGR due to higher prevalence of SLE in Europe.

Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune system to mistakenly attack health body tissue. In SLE, body immune system can affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever, Raynaud’s phenomenon, livedo reticularis, thrombosis, and myositis.

Get Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1149

It is also known as a disease of flare-ups and remissions and can range from mild to life threatening severity. It is also called as drug-induced lupus erythematosus due to common observation against drugs such as isoniazid, hydralazine and procainamide. Currently, there is no complete treatment for SLE. While only two biologic agents have been approved by FDA to treat SLE, synthetic drugs are still the mainstay of therapy in SLE. Based on available evidence, azathioprine and mycophenolate mofetil are the drugs of first choice. Hydroxychloroquine should be considered an anchor drug in SLE because of the multiple beneficial effects of this agent.

Systemic Lupus Erythematous (SLE) Drugs Market: Drivers & Restraints

Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing support for emerging research areas for new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment as well as consistent research and development processes for novel drug molecules are important drivers for global lupus erythematous market.

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-1149

Additionally, safety and quality of systemic lupus erythematous controlling therapy may possibly be a challenge for the growth of the global systemic lupus erythematous drugs market. Moreover, numerous public awareness programs targeted to increase awareness levels are also being accompanied. For instance, Lupus Foundation of America (LFA) has been implementing various projects to increase central support for SLE research and services to support people and families affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for new treatment options with better levels of efficacy and safety are obstructing the global systemic lupus erythematous drugs market.

Systemic Lupus Erythematous (SLE) Drugs Market: Segmentation

The global systemic lupus erythematous drugs market is classified on the basis of molecule and region.

Based on type of molecule, the global systemic lupus erythematous drugs market is segmented into the following:

Corticosteroids

Prednisone

Cortisone

Hydrocortisone

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

Over-the-counter NSAIDs include

Ibuprofen (Motrin)

Naproxen (Naprosyn)

Prescription versions include

Indomethacin (Indocin)

Nabumetone (RELAFEN)

Celecoxib (Celebrex)

Anti-Inflammatories

Aspirin

Acetaminophen (Tylenol)

For in-depth insights, Download a PDF Brochure@ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1149

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Hydroxychloroquine (Plaquenil).

Cyclosporine (Gengraf, Neoral, Sandimmune)

Azathioprine (Azasan, Imuran)

Antimalarials

Chloroquine (Aralen)

Hydroxychloroquine (Plaquenil)

BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)

Belimumab (Benlysta)

Immunosuppressive Agents/Immune Modulators

Azathioprine (Imuran)

Methotrexate (Rheumatrex)

Cyclophosphamide (Cytoxan)

Anticoagulants

Low-dose aspirin

Heparin (Calciparine, Liquaemin)

Warfarin (Coumadin)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Smart Wheelchair Market is expected to be at a CAGR of 7.8% from (2022-2032)

[322 Pages Report] The smart wheelchair market is subject to changes owing to the factors influencing the market such as the increasing prevalence of neurological disorders, rising awareness and demand for automated medical devices, increasing burden of the geriatric population globally, and the growing levels of disposable income of the target population.

According to the latest study conducted by Future Market Insights, the smart wheelchair market will be projected to be valued at US$ 162.6 Mn by the end of 2022 and is expected to exhibit a CAGR growth of 7.8% over the forecast period (2022-2032)

Although the independent movement is crucial, some wheelchair users find it difficult or impossible to operate conventional manual or motorised wheelchairs. Multiple overlapping physical, cognitive, or perceptual symptoms of diseases such as cerebral palsy, amyotrophic lateral sclerosis, cerebrovascular accident, multiple sclerosis, and spinal cord injury can make it difficult to use a wheelchair safely and independently. Varied forms of assistance from a smart wheelchair and different wheelchair form elements can benefit people with various symptom combinations.

Get Sample Report@  https://www.futuremarketinsights.com/reports/sample/rep-gb-15035

The COVID-19 pandemic had unprecedented effects on the world’s economy, along with sending the healthcare sector into a hyper drive. COVID-19 pandemic negatively influenced the smart wheelchair market during the peak of the pandemic in 2020, due to the shortage of supply of raw materials and other supply chain crises. However, the partial normalization of the world in 2021 opened up a foray of growth opportunities for the key players in this industry.

There are services in hospital settings where external consultations, tests, analyses, and procedures are conducted involving patient displacement. This is particularly important for those with balance and mobility issues caused by disability, pain, fractures, or abnormalities in the lower limbs. Patients are currently transported to hospitals by patient transporters. It could often be done in a wheelchair, which would be more beneficial, owing to its autonomy. As a result, delays and failures owing to a shortage of staff to carry out the transfer would be avoided.

Technological advancements are also shaping the growth of the smart wheelchairs industry for over a decade.

  • For instance, In November 2021, Sunrise Medical LLC. announced the launch of its new ZIPPIE® Sphynx™ an on the go, compact, easily transportable wheelchair that can fit within a compact car’s trunk according to the clients’ needs. The market is consolidated with a few key players dominating the industry.

Rising sedentary lifestyle, increasing popularity of ultra-lightweight smart wheelchairs, and increased focus on R&D for smart wheelchairs are some of the key trends of this market. The overall improved technology adoption globally will fuel the demand for smart wheelchairs and the market is likely to expand exponentially over the forecast period. (2022-2032)

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-15035

Key Players :

  • Medical Depot, Inc.
  • Permobil AB
  • Pride Mobility Products Ltd.
  • MEYRA GmbH
  • DEKA Research & Development Corp.
  • tmsuk company limited
  • Ottobock
  • WHILL Inc.
  • Invacare Corporation
  • Karman Healthcare, Inc.

Key Takeaways from this study:

  • The joystick based smart wheelchairs hold the highest market share of about 0% during the year 2021, expanding at a CAGR of 7.6% during the forecast period.
  • Mobility impairment by usage accounts for the largest market value share of more than 40% and is set to expand at a CAGR of 2%.
  • The healthcare settings as the end users hold a market share of 0% in 2021 with an expected CAGR growth of 6.8% during the forecasted years.
  • North America is a leading region for the global smart wheelchairs market during the year 2021, accounting for a market share of 0%.

“Growing patient awareness regarding smart wheelchairs would fuel the growth of this market globally” says an analyst of Future Market Insights.

Market Competition:

Acquisitions and expansion of existing facilities are some of the strategies adopted by leading manufacturers of the smart wheelchair industry such as Sunrise Medical and Permobil, to further their business and establish a stronger market presence.

  • In August 2020, Sunrise Medical announced the completion of a strategic acquisition of paediatric industry leaders, Leckey and Firefly, in order to extend its paediatric product and service portfolio.
  • In March 2022, Permobil, a leading player in the wheelchairs industry, announced an investment to expand their R&D and operations facility in Tennessee in order to expand their business.

For in-depth insights, Download a PDF Brochure@ https://www.futuremarketinsights.com/reports/brochure/rep-gb-15035

What does the report cover?

Future Market Insights offers a unique perspective and actionable insights on the smart wheelchairs market in its latest study, presenting a demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research is based on product-(joystick based smart wheelchairs and Bluetooth connected smart wheelchairs), usage-(mobility impairment, ocular disability, geriatric group, multiple disability and others), and end-user (healthcare settings, home care settings and public access), and across seven key regions of the world.

About Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here.

Key Market Segments Covered in the Smart Wheelchair Industry Research

By Product:

  • Joystick based Smart Wheelchairs
  • Bluetooth Connected Smart Wheelchairs

By Patient:

  • Mobility Impairment
  • Ocular Disability
  • Geriatric Group
  • Multiple-Disability
  • Others

By End-User:

  • Healthcare Settings
  • Home Care Settings
  • Public Access

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Hyaluronic Acid Products Market exhibiting growth at 6.1% CAGR through 2030

[284 Pages Report] Hyaluronic acid products have been gaining the momentum backed by massive use in therapies intended at the treatment of osteoarthritis, vesicoureteral reflux (VUR), and dry eye diseases, besides diverse aesthetic applications. Future Market Insights (FMI) in a new study has forecast the global market for hyaluronic acid products to surpass US$ 2.7 Bn by 2021.

As a result, the demand of minimally invasive treatment for diseases such as osteoarthritis and VUR stemmed. Manufacturers are introducing advanced intra-articular hyaluronic acid injections (IAHA) injections for the minimal invasive pain management with minimal pain, short recovery time and shorter hospital stay period.

The rising demand of the minimally invasive treatment for the pain management of osteoarthritis and other chronic ailments have pushed the key players to introduce innovative hyaluronic acid products into the market. The conventional treatment regime for chronic diseases was often invasive, involving certain amount of risk for patients with medical-comorbidities. These treatment methods often resulted in long hospital stays.

FMI has forecast dermal fillers to remain key application segment, accounting for over 35% of sales in 2021. The dermatological application of hyaluronic acid also has seen surge with the introduction of advanced dermal fillers, masks, and serums for application in restorative therapy and wrinkle augmentations.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-486

Major Key Players:

  • Anika Therapeutics, Inc.
  • Fidia Farmaceutici S.p.A.
  • Sanofi
  • Ferring B.V.
  • Viatris Inc.
  • Croma-Pharma
  • Seikagaku Corporation
  • Zimmer Biomet
  • Lifecore Biomedical, LLC
  • LG Chem
  • Bioventus LLC
  • Smith & Nephew plc
  • Shanghai Jingfeng Pharmaceutical Co., Ltd.
  • Nestle (Galderma)
  • Bausch Health Companies Inc. Companies Inc. (Salix Pharmaceuticals, Inc.)
  • Allergan Plc.

“Increasing prevalence of chronic inflammatory diseases, increasing geriatric population, and advancements in hyaluronic acid products in terms of better efficacy and cost-effectiveness, are expected to drive the hyaluronic acid products market,” says the FMI Analyst

The global hyaluronic acid products market is set to expand its scope in the forecast period, as a result of rising prevalence of chronic diseases and expanding geriatric population. In addition to this, the rising demand for minimally invasive therapies and advancing aesthetic procedures and products are propelling the growth of the market.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-486

Key Takeaways from Hyaluronic Acid Products Market Study

  • The hyaluronic acid products market will expand at a CAGR of 6.1% between 2020 and 2030
  • The U.S. will emerge as one of the leading markets, accounting for over 73% of sales in North America
  • The U.K. will remain one of the key markets within Europe, registering 7.7% Y-o-Y growth in 2021
  • The demand for Germany and France will continue rising at a positive rate
  • Japan will emerge as a leading market in East Asia, followed by China and South Korea

Who is winning?

Manufacturers in the hyaluronic acid products market are focusing on advanced IAHA injections, dermal filler, and other products. The delivery of hyaluronic acid to the target site has been made effective, precise, and minimally invasive. This is intended at ensuring more effective pain management for various chronic and inflammatory diseases such as osteoarthritis. Many manufacturers are focused on developing advanced, effective and affordable IAHA injections that come with advanced targeted delivery and minimal invasiveness.

For instance, Synvisc by Sanofi is effective for osteoarthritis pain. The advanced range of dermal filler launched by Galderma of Nestlé, named Restylane covers a wide spectrum dermal application for volume restorative therapy and Restylane Lyft is indicated for the wrinkle augmentation of the backside of the hand.

Valuable Insights into Hyaluronic Acid Products Market

Future Market Insights, in its new report, provides an unbiased analysis of the hyaluronic acid products market, presenting historical demand data (2015-2019) and forecast statistics for the period from 2020-2030. The study divulges compelling insights into the hyaluronic acid products market based on product type (single cycle injection, three cycle injection, five cycle injection), application (osteoarthritis, ophthalmic, dermal fillers, and vesicoureteral reflux), and distribution channel (hospital pharmacies, retail pharmacies, drug stores, and specialty clinics). Regionally the market covers North America, Europe, Latin America, East Asia, South Asia, Oceania, and the Middle East and Africa.

Hyaluronic Acid Products Market by Category

Product

  • Single Cycle Injection Products
  • Three Cycle Injection Products
  • Five Cycle Injection Products

Application

  • Osteoarthritis
  • Ophthalmic
  • Dermal Fillers
  • Vesicoureteral Reflux

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Speciality Clinics

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-486

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Middle East and Africa (MEA)
  • Oceania

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Carcinoid Syndrome Diarrhea Treatment Market Research, Top Company Profiles, Country-wise Insights to 2027

Carcinoid Syndrome Diarrhea Treatment Market: Drivers and Restraints

Carcinoid syndrome diarrhea treatment market would grow during the forecast years as many multi-national companies are focusing towards new product innovations in carcinoid syndrome diarrhea treatment. Also, the market for carcinoid syndrome diarrhea treatment would experience a boost as the treatment available for this disease are limited, and the company’s manufacturing drugs would target a wide market hence gaining huge market share in the carcinoid syndrome diarrhea treatment market.

According to American Cancer Society, the worldwide incidence of carcinoid tumor is estimated that approximately 8000 adults in the United States are diagnosed with a carcinoid tumor in the gastrointestinal tract. Other factors contributing to carcinoid syndrome diarrhea treatment market are increasing the incidence of hormonal disorders, growing smoking habits, and increasing prevalence of the disease. The market for carcinoid syndrome diarrhea treatment would be affected due to the low availability of therapeutic options for treatment of the disease.

Get Sample Free Sample of this Premium Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-3999

Carcinoid Syndrome Diarrhea Treatment Market: Region Wise Outlook

Geographically, the Carcinoid Syndrome Diarrhea Treatment market can be segmented into seven regions, North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is the most attractive region for the carcinoid syndrome diarrhea treatment market attributing to the increasing prevalence of the disease in this region.

Followed by which is Europe and Japan as the leading regions in carcinoid syndrome diarrhea treatment market. These markets are also growing significantly due to the focus on the new therapy developments for carcinoid syndrome diarrhea treatment which would ease in the reduction of incidence rare. Asia Pacific excluding Japan is also expected to show significant growth in carcinoid syndrome diarrhea treatment market due to increase in research and development activities, and development of healthcare infrastructure in this region. Asia-Pacific excluding Japan region has the presence of many small players which are operating at a regional level and contribute to a significant market share of the carcinoid syndrome diarrhea treatment market.

Talk to Analyst: https://www.futuremarketinsights.com/ask-question/rep-gb-3999

Carcinoid Syndrome Diarrhea Treatment Market: Segmentation

The market for Carcinoid Syndrome Diarrhea Treatment can be primarily segmented into the various therapy types, distribution channel, and regions:

By Therapy Types:

  • Chemotherapy
  • Somatostatin Analog (SSA) Therapy
  • Oral Therapy

By Distribution Channels:

  • Speciality Pharmacy
  • Retail Pharmacy
  • Prescription Drug Stores
  • Mail Order Pharmacy

Carcinoid Syndrome Diarrhea Treatment Market: Key Players

The major participants in the global carcinoid syndrome diarrhea treatment market are Lexicon Pharmaceuticals, Inc., Novartis International AG (Sandoz), Pharmascience Inc., Omega Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Biopharmaceuticals, Inc., Sirtex Medical Limited, BTG International Ltd among others.

Lexicon Pharmaceuticals, Inc.is the first company to gain approval by U.S. Food and Drug Administration for orally administered therapy drug for the treatment of carcinoid syndrome diarrhea. As the treatment available for carcinoid syndrome diarrhea are limited, multiple companies are focusing on increased research and development for new targeted delivery of disease and targeting huge market share. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and grades.

Buy this Report Now: https://www.futuremarketinsights.com/checkout/3999

The report covers exhaustive analysis on

  • Market Segments
  • Market Dynamics
  • Historical Actual Market Size, 2012 – 2016
  • Market Size & Forecast 2017 to 2027
  • Supply & Demand Value Chain
  • Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

3D Bio Printing Market to grow at 12.9% CAGR through 2030 | Report by FMI

Academic institutes and hospitals use 3D printing technology to develop various models for training purposes. The technology is increasing used in bio printing where biomaterials such as growth factors and cells are combined with bioink to create tissue-like structures that imitate natural tissues. The global 3D bioprinting market is estimated to surpass US$ 1.2 Bn by 2021, at the market CAGR of 13% during the forecast period (2020-2030), as per a new report by Future Market Insights (FMI).

3D Bioprinting Market – About the Report

[290 Pages Report] Increasing rate of medical device manufacturing across the world has been fuelling the demand for advanced technologies. 3D bioprinting is used to design medical devices. Leading medical device and pharmaceutical manufacturing companies are focusing on improving their product portfolio across the world. The demand in this market is expected to surge in response to the lack of organ donors in adequate number. With research and development (R&D) investment within the medical devices sector poised to rise significantly, the market will gain from increasing growth opportunities in the coming years.

In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for 3D bioprinting. The report tracks the global sales of 3D bioprinting in 20+ high-growth markets, along with analyzing the impact COVID-19 has on the medical device industry in general, and 3D bioprinting in particular. COVID-19 pandemic will show a negative impact on the 3D bioprinting market. Due to short term shut down of production facilities of medical device industries for first few months in 2020

Get Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-808

3D bioprinting has immense potential to facilitate organ transplants and drug discovery. 3D printing can copy the actual macro and micro-environment of human organs and tissues which can solve the organ transplant crisis. Advancements in 3D printing technology and its promising applications in the healthcare industry are expected to increase the sale of 3D bioprinting over the forecast period.

As per the report, the technology will find increasing application in orthopedic implants manufacturing. The orthopedic implants segment is in fact forecast to account for over 30% of the market in terms of application.

Key Takeaways from 3D bioprinting Marker Study

  • Exhibiting a little below 13% Y-o-Y growth in 2021, 3D bioprinting market will exhibit solid growth
  • The U.S. will register high demand, accounting for nearly 95% of sales in North America
  • Demand in U.K. is expected to rise significantly, exhibiting above 11% Y-o-Y growth in 2021
  • France and Germany too will register high demand
  • In East Asia, China and Japan are expected to emerge as key market

“Launch of innovative 3D printers and application of 3D bioprinting in tissue engineering and regenerative medicine, medical device manufacturing will augment the growth of global 3D bioprinting market” says the FMI Analyst

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-808

Acquisitions, Partnerships and expansion are key Strategic Focus of 3D bioprinting Market Players

Leading players in the 3D bioprinting market on strengthening their market position though the Acquisition, Partnerships and expansion. For Instance,

  • In January 2021, 3D Systems announced its regenerative and bioprinting solutions expansion by actively investing in the regenerative areas, in collaboration with United Therapeutics Corporation.
  • In December 2019, GE Healthcare Life Sciences collaborated with Advanced Solutions Life Sciences (ASLS), a Kentucky-based biotechnology firm, to build an integrated 3D bioprinter by combining their digital advanced technologies.
  • In January 2020, GE Healthcare Life Sciences introduced a new additive manufacturing (AM) facility in Umeå, Sweden that will be dedicated to integrating 3D-printed parts into the company’s production of bio manufacturing equipment. With $2 million in backing, the new center is expected to increase biopharma manufacturers’ access to state-of-the-art technologies

Who is Winning?

The global market is set to expand its scope in the forecast period, due to rising prevalence of orthopedic disease globally and adoption of 3D bioprinting at various stages of development of orthopedic implants by medical manufacturers. In addition to this, cost effectiveness and increase adaption of 3D bioprinting in dental and regenerative medicine application has augmented the sales of 3D bioprinting.

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-808

The key market players covered by FMI include

  • 3D Systems, Inc
  • GE Healthcare (Concept Laser, Arcam AB)
  • EOS GmbH Electro Optical Systems
  • Renishaw plc
  • Stratasys Ltd
  • EnvisionTEC
  • Formlabs, Inc And Organovo Holdings Inc and
  • Advanced Solutions Life Sciences

consolidating their positions through mergers, acquisitions and new product launches.

3D bioprinting Market by Category

Technology

  • Stereolithography (SLA)
  • Selective Laser Sintering
  • Electron Beam Melting
  • Fused Deposition Modeling (FDM)
  • Laminated Object Manufacturing (LOM
  • Inkjet Printing
  • Multi-phase Jet Solidification

Application

  • Surgical Simulation and Training Models
  • Prosthetic Devices
  • Tissue Engineering and Regenerative Medicine
  • Orthopedic Implants
  • Dental Implants
  • Medical Sensors
  • Others

End User

  • Medical Device Manufacturers
  • Pharmaceutical Companies
  • Research & Academic Institutions
  • Contract Research Organizations

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Middle East and Africa (MEA)
  • Oceania

About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Stool Management Systems Market is set to experience significant growth at 3.4% CAGR from 2022 to 2032

According to Future Market Insights (FMI), the demand for stool management systems is expected to rise significantly, reaching a market value of USD$ 166.5 Mn by the end of 2021.

Stool management systems are designed for bed ridden patients with fecal incontinence, a condition commonly known as bowel incontinence. These systems are used to prevent infections and reduce nursing time requirements.

The stool management systems are advantageous for older adults and patients suffering from constipation and fecal incontinence. Furthermore, it is also helpful for bed-ridden patients who may have been subject to aliments such as strokes, paralysis, or spinal injury.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3568

According to the World Bank, approximately 700 million people were aged 65 and above in the world in 2019. Consequently, the overall high incidence of geriatric populations is resulting in the expansion of the patient pool and the resultant increase in the demand for stool management systems globally.

Fecal incontinence issues are common around the world and it has a notable burden on the economy and healthcare systems of society. The condition has impacted the economic system including hospital charges and nursing charges. Stool management systems help in reducing the nursing time and other hospital expenses.

Key players are focusing on strengthening their mergers and acquisition portfolios, in addition to advancement in technologies and new product launches. Europe holds the highest share in the market due to a vast target demographic, the presence of major market players, and high healthcare expenditure in the region.

“Increasing geriatric population, technological advancements, and a rising focus on next-gen stool management systems will create lucrative growth opportunities through 2031,” says the Future Market Insights analyst.

Ask from Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-3568

Key Takeaways from Stool Management Systems Market Study

  • Systems are key to revenue generation in the stool management systems market surpassing accessories. They are likely to account for 63% value share by the end of the forecast period.
  • Luer-lock syringes will lead, with a valuation of over US$ 16 Bn by the end of 2021 owing to security in drug administration processes.
  • The U.S. accounts for more than 92% share in the North America market, and will witness growth backed by presence of a well-established healthcare sector.
  • Germany and France are leading countries in Europe and will account for more than 18% and 16% of the Europe market respectively in 2021.
  • Australia is the largest and fastest growing market in Oceania, exhibiting 6.2% CAGR during the forecast period.

Who is Winning?

The global stool management systems market is set to expand due to the rising number of people suffering from stool related ailments. Leading organizations within the market are set to focus on research for healthcare systems to offer increasingly effective treatment options for superior patient outcomes.

Some of the leading players in the stool management systems market include B. Braun Melsungen AG, Becton Dickinson, ConvaTec, Inc., Hollister Incorporated, Prosyn International Ltd., Consure Medical and others.

Buy Complete Report@ https://www.futuremarketinsights.com/checkout/3568

Want More Insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels that provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global stool management systems market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the stool management systems market on basis of the product type in detail, cover every aspect of the market such as systems, accessories and major regions.

Stool Management Systems Market by CategoryProduct Type

 

  • Systems
    • External Management Systems
    • Indwelling Collection Systems
      • With Irrigation
      • Without Irrigation
  • Accessories
    • Catheter Tubes
    • Luer-Lock Syringe
    • Collection Bag with Filter
    • Clinch Clamp

Region

  • North America
  • Europe
  • Oceania

About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Hypoparathyroidism Treatment Market is expected to expand at a CAGR close to 8% through 2031

Hypoparathyroidism is a rare endocrine disorder, which often results in levels of calcium and high levels of phosphate, which in turn results in the production of low or abnormal parathyroid (PTH) levels. According to a recent research report by Future Market Insights (FMI), the hypoparathyroidism treatment market is estimated to reach a valuation of US$ 717.7 Mn in 2021, and is projected to display a promising CAGR of approximately 8% through the end of the forecast period in 2031.

Hypothyroidism primarily arises from surgeries in the neck region. It is associated to accidental damage to the parathyroid gland. High prevalence of these surgeries is expected to boost the demand in the hypoparathyroidism treatment market. For instance, in the U.S., up to 115,000 people are diagnosed with the chronic hypoparathyroidism. The majority of the hypoparathyroidism cases are caused by anterior neck surgery, which accounts for up to 75% of the of all hypoparathyroidism cases. The remaining 25% cases are non-surgical or in very rare cases is linked to genetic disorders.

Furthermore, considering the rare occurrence of this medical condition, hypoparathyroidism has been designated as an orphan disease by the U.S. FDA and European Commission. This designation of orphan disease will help manufacturers to speed up their drug development processes, which leads to better availability of drugs for treatments of hypoparathyroidism.

Get Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7857

However, the unprecedented nature of the COVID-19 pandemic has had a significant impact on the development of drugs for rare diseases including those associated with hypoparathyroidism.  Preference now is being given to the development of life-savings drugs with greater focus on development of COVID-19 drugs and vaccines, thus halting or suspending existing clinical trials other than live saving drugs.

Also, this has led to the delay or postponement of enrolment of the new participants for clinical studies. Thus, the lack of sufficient data availability on the safety and effectiveness of treatments from clinical trials, will hurt short-term prospects. Clinical trials will gradually resume through 2021, and is anticipated to pick up pace during the forecast period.

Key Takeaways from Hypoparathyroidism Treatment Marker Study

  • Calcium supplements dominate the hypoparathyroidism treatment market growing 2x by 2031 owing to efficacy with hormonal therapy.
  • Parenteral route of administration is projected to grow at higher pace, driven by a rise in the number of clinical trials, and approval of new drugs which are influencing strong growth in this segment.
  • United States holds over 85% of the North America market for hypoparathyroidism treatments and will remain dominant owing to government incentives.
  • The U.K. will exhibit high demand, registering y-o-y growth at nearly 7% in 2021.
  • Germany and France will emerge as key markets within Europe.
  • China and India reflect high potential for growth on the back of a large subclinical patient pool for kidney disorders, diabetes, obesity, thyroid surgeries or head & neck surgery.

Growing cases of hypoparathyroidism and associated neck surgeries, coupled with an increase in patient awareness and screening, faster approvals and grants for product development, and favorable reimbursement scenarios, are major factors influencing market growth. Demand for biologics and the emergence of personalized medicine are some of the upcoming trends that are expected to generate significant growth opportunities for manufacturers operating in this space,” says the FMI Analyst

Product Approvals, and Expansion Strategies Gain the Focus of Drug Manufacturers

Prominent players in the hypoparathyroidism treatment market are focusing on receiving approvals and grants for the development of new drugs to cater to the growing cases of hypoparathyroidism, thus, enhancing their market presence. For instance,

  • In October 2020, Ascendis’s TransCon PTH was designated as orphan drug by the European commission (EC), which is approved for use to treat hypoparathyroidism in Europe.
  • In July 2020, ProLynx, received a Small Business Innovation Research (SIBR) grant from NIH to help fasten the development PTH (1, 34), a long acting parathyroid hormone that can be in a week to patients suffering from hypoparathyroidism.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-7857

Prominent players in the hypoparathyroidism treatment market is entering into the strategic agreements and collaborations at regional levels, with special focus on emerging economies. Major players are consolidating their positions through regional collaborations to strengthen their presence and increase their product reach in these countries.

Some of the leading companies operating in the market are:

  • Takeda Pharmaceutical Company Limited.
  • Entera Bio Ltd.
  • Amgen Inc.
  • Ascendis Pharma A/S
  • F. Hoffmann-La Roche Ltd
  • ProLynx, Inc.
  • Extend Biosciences, Inc.
  • BionPharma Inc.

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global hypoparathyroidism treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provide compelling insights on Hypoparathyroidism treatment market on the basis of product type (parathyroid hormone, vitamin D analogues, and calcium supplements), route of administration (oral, parenteral), and distribution channel (hospital pharmacy, retail pharmacy, and online sales) across four major regions.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-7857

Hypoparathyroidism Treatment MarketBy Product Type

  • Parathyroid Hormone
    • Natpara
    • Others
  • Vitamin D Analogue
    • Vitamin D2
    • Vitamin D3
  • Calcium Supplements

By Route of Administration

  • Oral
  • Parenteral

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific MEA

About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Electric Dental Handpiece Market is expected to reach a valuation in excess of US$ 450 Million by the end of 2028

[247 Pages Report] A new research report by Future Market Insights titled ‘Electric Dental Handpiece Market: Global Industry Analysis 2013–2021 and Opportunity Assessment 2022–2028’ gives clear insights on the market and its various segments. According to the analysis, the global electric dental handpiece market recorded a market value of over US$ 270 Mn in 2012, and is expected to reach a valuation in excess of US$ 450 Mn by the end of 2028. The market is anticipated to grow at a CAGR OF 5.2% during the forecast period. The market growth will make many companies focus solely on providing dental handpieces. Manufacturers are developing electric brushless motors to be used in various dental settings for a large number of applications. Tie-ups with distributors and other channel partners ensure continuous product availability and will help in expanding product reach both geographically and in non-traditional end use settings.

Request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-2012

A dental handpiece is an instrument used to hold dental burs, disks, or cups in order to perform tooth removal or to perform cleaning and polishing of teeth or restorative material. The instrument is available in two modalities that includes air driven and electrically driven handpieces. It is powered by either electric motor or air turbines.

Electric Dental Handpiece Market: Dynamics
The growth of the global electric dental handpiece market is helped by a lot of factors. Mostly the technological advancements have been a contributor in the market’s growth. The increase in dental disorders also plays a crucial role in augmenting market revenue. People have started using more artificial products and there is a visible increase in the carelessness towards teeth, which has increased the rate of dental disorders. There is also an increase in the spending of people on costly dental treatments.However not every region is economically stable, which makes certain countries within such regions incapable of purchasing these costly instruments. Stringent regulations on the manufacturing of dental devices in under developed regions can be a factor that restricts revenue growth of the global electric dental handpiece market.
Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-2012Segmental Analysis

  • Based on the regional analysis, North America dominates the market with a higher revenue share than other regions. However, Western Europe is expected to lead in terms of a high CAGR of 5.7% during the forecast period
  • Based on motor type, brushless motors is the dominating segment of the market, and it is also the fastest growing segment with a CAGR of 5.8% during the forecast period
  • In terms of end user, the dental clinics segment leads the market with the maximum revenue and the highest growth rate

Global Electric Dental Handpiece Market: Competitive Landscape

This research report lists the top companies in the market along with brief business profiles. These profiles include the current as well as the future strategies of the companies studied. According to the market analysis, A-dec Inc. held the maximum revenue share in 2016. Some of the other major players mentioned in the report include

  • KaVo Dental GmbH (Danaher Corporation)
  • Dentsply Sirona Inc.
  • Nakanishi Inc.
  • A-dec Inc.
  • Bien-Air Medical Technologies
  • SciCan Ltd.
  • DentalEZ Group
  • Brasseler USA
  • W&H Dentalwerk Bürmoos GmbH
  • Lares Research etc.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-2012

Key Segments of Electric Dental Handpiece Industry Survey Electric Dental Handpiece Market by Motor Type

  • Brush Motors
  • Brushless Motors

Electric Dental Handpiece Market by End User

  • Hospitals
  • Dental Clinics
  • Others

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs